Clinical Trials for Stomach Cancer

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, locally advanced unresectable or metastatic FAP-positive solid tumors receive intravenous LY4337713, an investigational lutetium-177 radioligand that targets fibroblast activation protein on cancer-associated fibroblasts to deliver radiation to tumors. Eligible cancers include pancreatic, breast, ovarian, gastric, colorectal, esophageal, and cholangiocarcinoma.

ClinicalTrials.gov ID: NCT07213791

PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with peritoneal-only metastatic gastric or GEJ adenocarcinoma (ECOG 0–2) receive standard systemic chemotherapy followed by preoperative laparoscopic HIPEC, then gastrectomy with cytoreductive surgery and intraoperative HIPEC. Aims to improve progression-free and overall survival in patients without extra-peritoneal metastases.

ClinicalTrials.gov ID: NCT07178808

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory, locally advanced or metastatic NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, esophageal or gastric/GEJ cancer, or cervical, endometrial, or ovarian cancer (ECOG 0–1) receive NRM-823 alone or with an immune checkpoint inhibitor. NRM-823 is an investigational T-cell engager intended to bring T cells into contact with tumor cells; its tumor-binding target has not been publicly confirmed.

ClinicalTrials.gov ID: NCT07182149

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, advanced CA19-9–expressing solid tumors and no standard treatment option likely to benefit them receive BNT329, an investigational CA19-9–directed antibody–drug conjugate carrying a topoisomerase I inhibitor. Cohorts test different dosing schedules, one with a CA19-9–targeting antibody given before BNT329; a previously treated pancreatic cancer cohort compares two BNT329 doses.

ClinicalTrials.gov ID: NCT07186842

A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or refractory, locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation receive once-daily oral PLX-61639 after approved treatment options have been exhausted or deemed unsuitable. PLX-61639 is an investigational degrader that recruits DCAF16 to eliminate SMARCA2, a protein on which SMARCA4-deficient tumors may depend.

ClinicalTrials.gov ID: NCT07284186

An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors who have exhausted, cannot tolerate, or lack standard treatment options receive MRG007 (ARR-217), an investigational antibody–drug conjugate targeting CDH17 and carrying the cytotoxic payload exatecan. Patients must have measurable disease, ECOG performance status 0–1, and tumor tissue available for CDH17 testing or be willing to undergo biopsy.

ClinicalTrials.gov ID: NCT07066657

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors who lack effective standard treatment receive intravenous JMT108, initially every 2 weeks, in dose-escalation and tumor-specific expansion cohorts. JMT108 is an investigational PD-1–targeted antibody–IL-15 fusion protein designed to block PD-1 and deliver IL-15 signaling preferentially to PD-1–positive immune cells.

ClinicalTrials.gov ID: NCT07317505

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.

ClinicalTrials.gov ID: NCT07517198

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and progressive locally advanced/unresectable or metastatic cervical/vulvar cancer, small-cell lung cancer, gastric/GEJ cancer, or pancreatic ductal adenocarcinoma after standard options receive IV AVA6103 monotherapy on q2w or q3w schedules. AVA6103 is a FAP-activated exatecan peptide-drug conjugate designed to release a topoisomerase I inhibitor payload in the tumor microenvironment.

ClinicalTrials.gov ID: NCT07454642

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with SSTR-PET–positive, well-differentiated grade 1–3 metastatic or unresectable neuroendocrine tumors, with expansion cohorts including GEP-NETs, other SSTR-expressing NETs, and grade 1–3 meningiomas; prior radiopharmaceutical therapy such as lutetium-177 is excluded. Treatment is IV RYZ401, an investigational actinium-225–labeled somatostatin receptor–targeted alpha radiopharmaceutical designed to deliver radiation to SSTR/SSTR2-expressing tumor cells, given approximately every 6 weeks for 2–4 cycles.

ClinicalTrials.gov ID: NCT07165132